Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Acromegaly is a chronic disease caused by excessive secretion of growth hormone (GH) and mainly due to benign tumour localized in the pituitary gland. The disease develops insidiously, causing a gradual progression of symptoms; consequently most patients are diagnosed in their fourth decade of life. Administration of somatostatin analogues such as lanreotide have been shown to result in normalisation or the decrease of GH and insulin growth factor (IGF-1) levels and improvement of clinical symptoms in acromegalic patients. The purpose of this study is to evaluate whether lanreotide is also effective on tumour volume reduction (tumour shrinkage) and the benefits of this potential tumour shrinkage on disease symptoms and patient’s quality of life.
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Acromegaly is a chronic disease caused by excessive secretion of growth hormone (GH) and mainly due to benign tumour localized in the pituitary gland. The disease develops insidiously, causing a gradual progression of symptoms; consequently most patients are diagnosed in their fourth decade of life. Administration of somatostatin analogues such as lanreotide have been shown to result in normalisation or the decrease of GH and insulin growth factor (IGF-1) levels and improvement of clinical symptoms in acromegalic patients. The purpose of this study is to evaluate whether lanreotide is also effective on tumour volume reduction (tumour shrinkage) and the benefits of this potential tumour shrinkage on disease symptoms and patient’s quality of life.
Related Clinical Trials
![A study to evaluate the effect of phenytoin or itraconazole on the circulating levels of IPN60130 in healthy adult participants A study to evaluate the effect of phenytoin or itraconazole on the circulating levels of IPN60130 in healthy adult participants](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/defaultImg.png)
A study to evaluate the effect of phenytoin or itraconazole on the circulating levels of IPN60130 in healthy adult participants
![A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ?14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies. A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ?14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/defaultImg.png)
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ?14 Years With Fibrodysplasia Ossificans Progressiva...
![A study to assess whether adding maintenance cabozantinib (XL184) to best supportive care helps children, adolescents and young adults with osteosarcoma. A study to assess whether adding maintenance cabozantinib (XL184) to best supportive care helps children, adolescents and young adults with osteosarcoma.](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/defaultImg.png)
A study to assess whether adding maintenance cabozantinib (XL184) to best supportive care helps children, adolescents and young adults with osteosarcoma.
![A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/defaultImg.png)
A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults
![A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/defaultImg.png)
A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults
![A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity. A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/defaultImg.png)
A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
![A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/defaultImg.png)
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
![Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/defaultImg.png)
Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours
![Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/defaultImg.png)
Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia
![Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia. Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/defaultImg.png)